SILENCE THERAPEUTICS PLC-ADR (SLN) Stock Price, Quote, News and Overview
NASDAQ:SLN - Nasdaq - US82686Q1013 - ADR - Currency: USD
SLN Quote, Performance and Key Statistics
4.79
-0.21 (-4.2%)
The current stock price of SLN is 4.79 USD. In the past month the price decreased by -11.46%. In the past year, price decreased by -79.58%.
SLN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About SLN
Company Profile
Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a United Kingdom-based biotechnology company. The firm is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The firm's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. The company also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
Company Info
SILENCE THERAPEUTICS PLC-ADR
72 Hammersmith Road
London W14 8TH GB
CEO: Mark Rothera
Employees: 109
Company Website: https://www.silence-therapeutics.com/
Phone: 442034576900
SILENCE THERAPEUTICS PLC-ADR / SLN FAQ
What is the stock price of SILENCE THERAPEUTICS PLC-ADR today?
The current stock price of SLN is 4.79 USD. The price decreased by -4.2% in the last trading session.
What is the ticker symbol for SILENCE THERAPEUTICS PLC-ADR stock?
The exchange symbol of SILENCE THERAPEUTICS PLC-ADR is SLN and it is listed on the Nasdaq exchange.
On which exchange is SLN stock listed?
SLN stock is listed on the Nasdaq exchange.
What is SILENCE THERAPEUTICS PLC-ADR worth?
SILENCE THERAPEUTICS PLC-ADR (SLN) has a market capitalization of 226.16M USD. This makes SLN a Micro Cap stock.
How many employees does SILENCE THERAPEUTICS PLC-ADR have?
SILENCE THERAPEUTICS PLC-ADR (SLN) currently has 109 employees.
What are the support and resistance levels for SILENCE THERAPEUTICS PLC-ADR (SLN) stock?
SILENCE THERAPEUTICS PLC-ADR (SLN) has a resistance level at 5.01. Check the full technical report for a detailed analysis of SLN support and resistance levels.
Should I buy SILENCE THERAPEUTICS PLC-ADR (SLN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SLN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SLN, evaluating the profitability, health, valuation and growth aspects
- SILENCE THERAPEUTICS PLC-ADR (SLN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SILENCE THERAPEUTICS PLC-ADR (SLN) Sales and EPS estimates to see what analysts future expectations are.
- SILENCE THERAPEUTICS PLC-ADR (SLN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SILENCE THERAPEUTICS PLC-ADR (SLN) Insider and Institutional Ownership to learn about the owners and their transactions.
- SILENCE THERAPEUTICS PLC-ADR (SLN) Stock Chart to make your own analysis
- SILENCE THERAPEUTICS PLC-ADR (SLN) Latest news and press-releases to stay up to date.
Does SILENCE THERAPEUTICS PLC-ADR (SLN) stock pay dividends?
SLN does not pay a dividend.
When does SILENCE THERAPEUTICS PLC-ADR (SLN) report earnings?
SILENCE THERAPEUTICS PLC-ADR (SLN) will report earnings on 2025-03-12, before the market open.
What is the Short Interest ratio of SILENCE THERAPEUTICS PLC-ADR (SLN) stock?
The outstanding short interest for SILENCE THERAPEUTICS PLC-ADR (SLN) is 1.31% of its float. Check the ownership tab for more information on the SLN short interest.
SLN Technical Analysis
SLN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SLN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to SLN. The Buy consensus is the average rating of analysts ratings from 5 analysts.